Young-Suk Lim, Sang Hoon Ahn, Jae-Jun Shim, Homie Razavi, Devin Razavi-Shearer, Dong Hyun Sinn
Summary
Antiviral treatment in patients with chronic hepatitis B (CHB) may decrease the risk of hepatocellular carcinoma (HCC) and death. However, only 2.2% of CHB patients receive antiviral treatment globally. The complexity and strictness of the current clinical practice guidelines may limit expanding the treatment coverage for CHB. We examined the impact of expanding treatment criteria on future disease burden in Korea, a hepatitis B virus (HBV) endemic country with high diagnostic rates (74.2%).
English 
Spanish 
French 
Russian 
Arabic